Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C

Table 1 Comparison of baseline data between the two groups, n = 289

Variable	Generic, n (%)	Brand, n (%)	t (χ2)a statistic	P
Total	140	149
Age (yr)			9.23a	0.01
< 40	52 (37.1)	33 (22.1)
40-65	73 (52.1)	103 (69.1)
> 65	15 (10.7)	13 (8.7)
Sex			0.23a	0.63
Female	59 (42.1)	67 (45.0)
Male	81 (57.9)	82 (55.0)
Co-morbidities			32.28a	< 0.001
None	65 (46.4)	25 (16.8)
one to two	61 (43.6)	85 (57.0)
More than two	14 (10.0)	39 (26.2)
USD cirrhosis			15.10a	< 0.001
No	113 (80.7)	89 (59.7)
Yes	27 (19.3)	60 (40.3)
HCV genotype			9.86a	0.02
1	88 (62.9)	109 (73.2)
2	4 (2.9)	2 (1.3)
3	33 (23.6)	16 (10.7)
4	15 (10.7)	22 (14.8)
WBC (× 109/L) ± SD	6.26 ± 3.34	5.82 ± 2.15	1.37	0.17
Haemoglobin (g/dL) ± SD	12.50 ± 2.52	12.80 ± 2.12	-1.1	0.27
Platelets (× 109/L) ± SD	232.35 ± 108.08	189.01 ± 95.48	3.62	< 0.001
PT (sec) ± SD	14.11 ± 11.94	13.3 ± 1.88	0.8	0.43
PTT (sec) ± SD	24.16 ± 2.94	26.21 ± 3.79	-5.1	< 0.001
INR ± SD	1.08 ± 0.18	1.31 ± 2.22	-1.2	0.23
Creatinine (μmol/L) ± SD	66.86 ± 21.07	89.68 ± 148.85	-1.8	0.07
Albumin (g/L) ± SD	41.04 ± 5.11	38.81 ± 6.05	3.36	0.01
Total bilirubin (μmol/L) ± SD	17.68 ± 15.62	18.72 ± 18.26	-0.52	0.6
ALP (U/L) ± SD	93.31 ± 43.54	102.02 ± 43.79	-1.7	0.09
ALT (U/L) ± SD	71.66 ± 57.59	61.96 ± 41.47	1.65	0.1
gGT(U/L) ± SD	84.44 ± 109.99	101.76 ± 92.69	-1.45	0.15

^aP values based on Chi-square test or Student’s t-test as appropriate.

Data are presented as proportion (%) or mean ± SD or number. HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase.